Uma doença de nascença causada por alterações no gene IKBKAP. Ela se caracteriza por afetar as partes do sistema nervoso que controlam funções automáticas do corpo, como a digestão e os batimentos cardíacos, e também as partes responsáveis pela sensibilidade, como o tato e a percepção de dor.
Introdução
O que você precisa saber de cara
Uma doença de nascença causada por alterações no gene IKBKAP. Ela se caracteriza por afetar as partes do sistema nervoso que controlam funções automáticas do corpo, como a digestão e os batimentos cardíacos, e também as partes responsáveis pela sensibilidade, como o tato e a percepção de dor.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 25 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 61 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.
Component of the elongator complex which is required for multiple tRNA modifications, including mcm5U (5-methoxycarbonylmethyl uridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), and ncm5U (5-carbamoylmethyl uridine) (PubMed:29332244). The elongator complex catalyzes the formation of carboxymethyluridine in the wobble base at position 34 in tRNAs (PubMed:29332244). Regulates the migration and branching of projection neurons in the developing cerebral cortex, through a process depending on
CytoplasmNucleus
Neuropathy, hereditary sensory and autonomic, 3
A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by sensory and/or autonomic abnormalities. HSAN3 patients manifest a variety of symptoms such as alacrima, decreased taste, decreased sensitivity to pain and temperature, vasomotor instability, hypoactive or absent deep tendon reflexes, vomiting crises, and gastrointestinal dysfunction.
Medicamentos e terapias
Mecanismo: DOPA decarboxylase inhibitor
Mecanismo: DOPA decarboxylase inhibitor
Variantes genéticas (ClinVar)
471 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 1,046 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
1 via biológica associada aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Disautonomia familiar
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
14 ensaios clínicos encontrados, 3 ativos.
Publicações mais relevantes
AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.
Familial dysautonomia (FD) is a rare autosomal recessive neurodegenerative disorder caused by a splicing mutation in the ELP1 gene. It predominantly affects the sensory and autonomic nervous systems, with progressive vision loss due to optic neuropathy being a universal and debilitating symptom. Retinal pathology in FD involves progressive thinning of the retinal nerve fiber layer (RNFL), resulting from the degeneration of retinal ganglion cells (RGCs). Notably, FD-associated vision loss has a postnatal onset, offering a critical window for therapeutic intervention before severe visual impairment develops in adolescence. Currently, no approved treatments exist to prevent or reverse vision loss in FD. In this study, we present a novel RNA-based therapeutic approach targeting ELP1 pre-mRNA splicing in the retina. We engineered exon-specific U1 small nuclear RNAs (ExSpeU1s) to enhance inclusion of exon 20 in the mutant ELP1 transcripts in the retina, thereby restoring full-length ELP1 expression. Delivery of ExSpeU1 via adeno-associated virus serotype 2 (AAV2) to the retina improved ELP1 splicing, rescued RGC loss, and visual function in an FD mouse model. These findings highlight ExSpeU1-mediated splicing correction as a promising therapeutic approach for treating optic neuropathy in FD, offering potential to preserve vision and improve quality of life for patients.
Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.
The Unified Multiple System Atrophy Rating Scale (UMSARS) is widely used as an outcome measure in MSA trials, but it has limitations for clinical trial use. To address these, we developed the Multiple System Atrophy Combined Outcome Assessment (MuSyCA), a comprehensive multimodal tool for disease-modifying MSA trials. The purpose of this manuscript is to describe the development and validation plan for MuSyCA, with emphasis on its structure, intended use, and assessment of reliability, validity, and sensitivity in tracking disease progression. The development of MuSyCA followed a multistep process. Candidate outcome assessments were identified through systematic literature review and analysis of longitudinal data from large MSA cohorts. Content was refined through multiple Delphi-like consensus rounds involving MSA experts, patient advocacy groups representatives, and industry stakeholders. Cognitive interviews conducted in 20 patients with MSA evaluated the clarity and clinical relevance of patient- and clinician-reported outcomes; feedback was incorporated into a subsequent version of the MuSyCA. Validation is ongoing and includes assessment of construct validity, internal consistency, test-retest reliability, and responsiveness. Longitudinal analyses to determine sensitivity to change over time are ongoing. MuSyCA combines patient- and clinician-reported outcomes, biomarkers (neurofilament light chain, neuroimaging), and performance-based measures to capture subjective and objective aspects of MSA progression, enhancing its utility to detect treatment effects in clinical trials. MuSyCa is not intended to be used in clinical practice. MuSyCA offers a multidimensional approach to MSA assessment, supporting precise, disease-relevant evaluations in trials of putative disease-modifying therapies. Its validation will provide a standardized multimodal outcome measure, advancing MSA therapeutic development.
ELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.
Familial dysautonomia (FD) is an autosomal recessive sensory and autonomic neurodevelopmental and degenerative disorder characterized by complex neurological phenotypes. One of its most debilitating features is progressive optic neuropathy, which leads to severe visual impairment in FD patients by the third decade of life. Although several preclinical approaches have shown partial rescue of retinal ganglion cell (RGC) degeneration through increasing Elongator acetyltransferase complex subunit 1 (ELP1) expression in the retina, currently no treatments exist to prevent vision loss in FD. In this study, we performed a comprehensive analysis of visual function in a retina-specific FD mouse model ( Pax6-Cre ⁺ ;Elp1 loxp/loxp ) and evaluated a gene supplementation strategy to restore human ELP1 protein levels in the retina. Longitudinal retinal assessments indicated that FD mice exhibit significant retinal nerve fiber layer (RNFL) thinning, as observed in FD patients. FD mice also showed reduced flash visual evoked potentials (VEPs), pattern electroretinography (pERGs), and photopic negative responses (phNRs) amplitudes, along with impaired visual acuity and contrast sensitivity, as assessed using optomotor response assay (OMR). Full-field electroretinography (ffERG) revealed reduced amplitude of dark-adapted a-waves, dark and light-adapted b-waves, indicating combined RGC and bipolar cell dysfunction. Intravitreal delivery of an adeno associated vector (AAV) vector (AAV2.U1a.hELP1) effectively restored physiological ELP1 protein expression, which resulted in a significant rescue of retinal structure and function. Gene supplementation with AAV2.U1a.hELP1 resulted in broad functional and structural improvement compared with untreated FD mice. In summary, our findings provide the first demonstration that ELP1 gene supplementation can effectively rescue RGC function in an FD mouse model and support AAV2.hELP1 at an optimized dose (5.4×10 8 vg) as a promising therapeutic approach for FD-associated optic neuropathy.
Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).
Establish the minimally clinically important difference (MCID) for the Orthostatic Hypotension Questionnaire (OHQ). Neurogenic orthostatic hypotension (nOH) causes disabling symptoms that impair daily function and quality of life. The OHQ is a validated patient-reported outcome with a symptom assessment (OHSA) and daily activity scale (OHDAS), widely used in clinical trials, despite the MCID being unestablished. We analyzed data from two phase 3, randomized placebo-controlled trials (SEQUOIA and REDWOOD), evaluating ampreloxetine for symptomatic nOH in patients with Parkinson disease, multiple system atrophy, and pure autonomic failure. Using anchor-based and distribution-based methods, we calculated the MCID for the total OHQ score, OHSA and OHDAS composite subscales, and for the single dizziness/lightheadedness question (OHSA1). The analysis included 184 subjects from SEQUOIA and 128 from REDWOOD. The total OHQ MCID for improvement was a reduction of 0.9-1.2 points and for worsening was an increase of 0.7-1.1 points. The MCID for the OHSA composite ranged from a reduction of 0.9-1.3 points for improvement and an increase of 0.7-1.1 points for worsening. For the single-item OHSA1, the MCID was a reduction of 2.0-3.0 points for improvement and an increase of 1.0 point for worsening. Owing to poor correlation with the symptom-based anchors, a reliable MCID for the OHDAS component was not established. These MCID thresholds for the OHQ, OHSA and OHSA item 1 alone, enhance the interpretability of scores and support their use in evaluating clinical benefit.
Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.
Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue-specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations. A blood-based ELP-1 protein assay may provide a reliable way to monitor gene target engagement. Using a newly developed radioimmunoassay, we quantified ELP1 protein levels in peripheral blood samples collected from 59 homozygous FD patients carrying the IVS20 + 6T>C mutation and 66 heterozygous carriers. To assess the reproducibility of the measurement, replicate samples were collected in 43 participants. Longitudinal variability was evaluated in 22 participants who underwent repeat sampling 1 year later. ELP1 protein levels were significantly lower in FD patients compared to heterozygous carriers (244 ± 75 vs. 2210 ± 1031 pg/mL, p < 0.001). Replicate analysis of 43 paired samples showed strong consistency in ELP1 levels (p < 0.000). Repeat measurements 1 year after baseline showed longitudinal stability (R2 = 0.827, p < 0.001). An ELP1 threshold of 492 pg/mL yielded a sensitivity of 80.2% (CI of 70.6 to 87.2%) and a specificity of 98.2% (95% CI of 90%-99%) with a positive likelihood ratio of 46.5, indicating that individuals with FD were over 46 times more likely to have ELP1 levels below this threshold compared to non-affected carriers. Blood ELP1 levels are robust and reproducible, with concentrations below 492 pg/mL strongly indicative of disease. Moreover, given their longitudinal stability, ELP1 can serve as a marker of target engagement to evaluate the efficacy of gene-targeted therapies aimed at correcting ELP1 gene splicing and protein production.
Publicações recentes
Prime editing of the common Familial Dysautonomia-causing c.2204 + 6T > C splicing mutation.
Peripheral neuron phenotypes of familial dysautonomia are rescued by AAV-mediated gene therapy.
ELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.
AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.
Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.
📚 EuropePMC545 artigos no totalmostrando 172
Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.
bioRxiv : the preprint server for biologyAAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.
Molecular therapy. Nucleic acidsExploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.
Annals of clinical and translational neurologyA Rare Co-Occurrence of Gastric Heterotopia and Autonomic Nervous System Dysfunction: An Attempt to Explain If There Is a Need to Explore Possible Syndromic Link.
Journal of medical casesEstablishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyPeripheral neuron phenotypes of familial dysautonomia are rescued by AAV-mediated gene therapy.
Research squareAAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in a mouse model of familial dysautonomia.
bioRxiv : the preprint server for biologyReproductive carrier screening for genetic disorders: position statement of the Canadian College of Medical Geneticists.
Journal of medical geneticsAltered Pain Perception in a Young Adult with Childhood Trauma and Suspected Riley-Day Syndrome: A Case Report.
Reports (MDPI)Spine surgery and complication in familial dysautonomia: a case report.
Frontiers in surgeryAdvances in the treatment of familial dysautonomia: what does the future hold?
Expert review of neurotherapeuticsBone Mineral Density and Trabecular Bone Score in Children, Adolescents and Young Adults with Familial Dysautonomia.
Calcified tissue internationalCarbidopa: beyond Parkinson's disease.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyEngineered CRISPR-Base Editors as a Permanent Treatment for Familial Dysautonomia.
bioRxiv : the preprint server for biologyLaminin β4 is required for the development of human peripheral sensory neurons.
bioRxiv : the preprint server for biologyGenipin rescues developmental and degenerative defects in familial dysautonomia models and accelerates axon regeneration.
Science translational medicineElp1 function in placode-derived neurons is critical for proper trigeminal ganglion development.
Developmental dynamics : an official publication of the American Association of AnatomistsAtomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyNeuronal and glial cell alterations involved in the retinal degeneration of the familial dysautonomia optic neuropathy.
GliaMetabolic Deficits in the Retina of a Familial Dysautonomia Mouse Model.
MetabolitesELP1, the Gene Mutated in Familial Dysautonomia, Is Required for Normal Enteric Nervous System Development and Maintenance and for Gut Epithelium Homeostasis.
The Journal of neuroscience : the official journal of the Society for NeuroscienceLoss of Elp1 in cerebellar granule cell progenitors models ataxia phenotype of Familial Dysautonomia.
Neurobiology of diseaseAge-dependent regulation of ELP1 exon 20 splicing in Familial Dysautonomia by RNA Polymerase II kinetics and chromatin structure.
PloS oneAuthor Correction: Transcriptome analysis in a humanized mouse model of familial dysautonomia reveals tissue-specific gene expression disruption in the peripheral nervous system.
Scientific reportsParasympathetic neurons derived from human pluripotent stem cells model human diseases and development.
Cell stem cellRetrograde tubing as a rescue treatment for megaoesophagus: a case report.
BMJ open gastroenterologySkin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies.
JAMASpecificity, synergy, and mechanisms of splice-modifying drugs.
Nature communicationsLinking the Extended Autonomic System with the Homeostat Theory: New Perspectives about Dysautonomias.
Journal of personalized medicineTranscriptome analysis in a humanized mouse model of familial dysautonomia reveals tissue-specific gene expression disruption in the peripheral nervous system.
Scientific reportsThe Relationship Between Scoliosis, Spinal Bone Density, and Truncal Muscle Strength in Familial Dysautonomia Patients.
Calcified tissue internationalHeight, weight, and body mass index in patients with familial dysautonomia.
PloS oneReduction of retinal ganglion cell death in mouse models of familial dysautonomia using AAV-mediated gene therapy and splicing modulators.
Scientific reportsLong-Term Outcomes of Hyperadrenergic Orthostatic Hypotension.
Research squareAutonomic failure: Clinicopathologic, physiologic, and genetic aspects.
Handbook of clinical neurologyMarine alkaloid rigidin analogues as potential selective inhibitors of SHP1, a new strategy for cancer immunotherapeutics.
Journal of biomolecular structure & dynamicsThe future of rare autonomic disease research.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyApparently rare cases are worth studying because….
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietySensorimotor control in the congenital absence of functional muscle spindles.
Experimental physiologyGenipin Crosslinks the Extracellular Matrix to Rescue Developmental and Degenerative Defects, and Accelerates Regeneration of Peripheral Neurons.
bioRxiv : the preprint server for biologyA Comprehensive NMR Analysis of Serum and Fecal Metabolites in Familial Dysautonomia Patients Reveals Significant Metabolic Perturbations.
MetabolitesA novel ELP1 mutation impairs the function of the Elongator complex and causes a severe neurodevelopmental phenotype.
Journal of human geneticsDevelopment of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomia.
American journal of human geneticsGastrointestinal bleeding in children with familial dysautonomia: a case-control study.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyGut microbiome dysbiosis drives metabolic dysfunction in Familial dysautonomia.
Nature communicationsNorepinephrine transporter defects lead to sympathetic hyperactivity in Familial Dysautonomia models.
Nature communicationsElongator promotes neuritogenesis via regulation of tau stability through acly activity.
Frontiers in cell and developmental biologyExperience With Dexmedetomidine Use in the Treatment of Dysautonomic Crisis in Familial Dysautonomia: An Off-Label Use.
CureusCounter pressure maneuvers for syncope prevention: A semi-systematic review and meta-analysis.
Frontiers in cardiovascular medicineJaw-in-a-Riley-Day: Mandibular Free Flap Reconstruction With Virtual Surgical Planning in a Patient With Familial Dysautonomia.
CureusRescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA.
American journal of human geneticsDiagnosis and treatment of orthostatic hypotension.
The Lancet. NeurologyCommentary: Congenital corneal anesthesia: A rare form of type-4 familial dysautonomia.
Indian journal of ophthalmologyEngineered U1 snRNAs to modulate alternatively spliced exons.
Methods (San Diego, Calif.)Loss of Elp1 disrupts trigeminal ganglion neurodevelopment in a model of familial dysautonomia.
eLifeCarnosol, a diterpene present in rosemary, increases ELP1 levels in familial dysautonomia patient-derived cells and healthy adults: a possible therapy for FD.
Human molecular geneticsA Closer Look at Familial Dysautonomia from a Social Communication Perspective: A Case Report and Review of Literature.
Psychiatry and clinical psychopharmacologyAAMR syndrome in a 22-month-old and literature review.
Ophthalmic geneticsElp1 is required for development of visceral sensory peripheral and central circuitry.
Disease models & mechanismsNeuropathic-like Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
The Journal of clinical endocrinology and metabolismSelective retinal ganglion cell loss and optic neuropathy in a humanized mouse model of familial dysautonomia.
Human molecular geneticsDevelopmental regulation of neuronal gene expression by Elongator complex protein 1 dosage.
Journal of genetics and genomics = Yi chuan xue baoAuthor Correction: Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia.
Nature communicationsATP-citrate lyase promotes axonal transport across species.
Nature communicationsLoss of Elp1 perturbs histone H2A.Z and the Notch signaling pathway.
Biology openInduced pluripotent stem cell (iPSC) lines from two individuals carrying a homozygous (BGUi007-A) and a heterozygous (BGUi006-A) mutation in ELP1 for in vitro modeling of familial dysautonomia.
Stem cell researchTherapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia.
Nature communicationsThe case of a patient with MIRAGE syndrome with familial dysautonomia-like symptoms.
Human genome variationUncommon side effects of common drugs in patients with familial dysautonomia.
Pharmacoepidemiology and drug safetyRecurrent abdominal pain in hereditary sensory autonomic neuropathy type II (HSAN-II).
Revue neurologiqueA deep learning approach to identify gene targets of a therapeutic for human splicing disorders.
Nature communicationsBone biomechanical properties and tissue-scale bone quality in a genetic mouse model of familial dysautonomia.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAFludrocortisone for orthostatic hypotension.
The Cochrane database of systematic reviewsLimitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyDerivation of Peripheral Nociceptive, Mechanoreceptive, and Proprioceptive Sensory Neurons from the same Culture of Human Pluripotent Stem Cells.
Stem cell reportsRetrograde nerve growth factor signaling abnormalities and the pathogenesis of familial dysautonomia.
Neural regeneration researchCytoprotective activities of kinetin purine isosteres.
Bioorganic & medicinal chemistryLongitudinal changes in the macula and optic nerve in familial dysautonomia.
Journal of neurologyGenetically Established Familial Amyloidotic Polyneuropathy from India: Narrating the Diagnostic "Odyssey" and a Mini Review.
Neurology IndiaFrequency and burden of gastrointestinal symptoms in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyVon Economo Neuron Pathology in Familial Dysautonomia: Quantitative Assessment and Possible Implications.
Journal of neuropathology and experimental neurologyClinical and confocal imaging findings in congenital corneal anaesthesia.
The British journal of ophthalmologyDevelopment of the Autonomic Nervous System: Clinical Implications.
Seminars in neurologyAfferent Baroreflex Dysfunction: Decreased or Excessive Signaling Results in Distinct Phenotypes.
Seminars in neurologyAcute Sensory and Autonomic Neuronopathy: A Devastating Disorder Affecting Sensory and Autonomic Ganglia.
Seminars in neurologyCarbidopa for Afferent Baroreflex Failure in Familial Dysautonomia: A Double-Blind Randomized Crossover Clinical Trial.
Hypertension (Dallas, Tex. : 1979)The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension.
Parkinsonism & related disordersElbow proprioception is normal in patients with a congenital absence of functional muscle spindles.
The Journal of physiologyRetrograde nerve growth factor signaling abnormalities in familial dysautonomia.
The Journal of clinical investigation(H)Elping nerve growth factor: Elp1 inhibits TrkA's phosphatase to maintain retrograde signaling.
The Journal of clinical investigationImpact of a national genetic carrier-screening program for reproductive purposes.
Acta obstetricia et gynecologica ScandinavicaHereditary Sensory and Autonomic Neuropathies: Adding More to the Classification.
Current neurology and neuroscience reportsGeneration of Neural Crest Progenitors from Human Pluripotent Stem Cells.
Methods in molecular biology (Clifton, N.J.)ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia.
American journal of human geneticsChemoreflex failure and sleep-disordered breathing in familial dysautonomia: Implications for sudden death during sleep.
Autonomic neuroscience : basic & clinicalCombinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients.
PloS oneQuantitative magnetic resonance evaluation of the trigeminal nerve in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyPatient-Derived Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Disease Modeling and Therapeutic Discovery.
Chronic obstructive pulmonary diseases (Miami, Fla.)Autonomic Neurons with Sympathetic Character Derived From Human Pluripotent Stem Cells.
Current protocols in stem cell biologyImprovement of daytime hypercapnia with nocturnal non-invasive ventilation in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyInduced pluripotent stem cells for disease modeling, cell therapy and drug discovery in genetic autonomic disorders: a review.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyLong-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization.
The ocular surfaceResting Energy Expenditure in Patients With Familial Dysautonomia: A Preliminary Study.
Journal of pediatric gastroenterology and nutritionDevelopment of a Screening Platform to Identify Small Molecules That Modify ELP1 Pre-mRNA Splicing in Familial Dysautonomia.
SLAS discovery : advancing life sciences R & DCase Series: Management of Neurotrophic Keratitis from Familial Dysautonomia.
Optometry and vision science : official publication of the American Academy of OptometryRespiratory care in familial dysautonomia: Systematic review and expert consensus recommendations.
Respiratory medicineRetina-specific loss of Ikbkap/Elp1 causes mitochondrial dysfunction that leads to selective retinal ganglion cell degeneration in a mouse model of familial dysautonomia.
Disease models & mechanismsOrthostatic hypotension: does the heart rate matter? And other updates on recent autonomic research.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyBlocking of an intronic splicing silencer completely rescues IKBKAP exon 20 splicing in familial dysautonomia patient cells.
Nucleic acids researchExon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model.
Human molecular geneticsCharacteristics of ataxic gait in familial dysautonomia patients.
PloS onePrevalence and characteristics of sleep-disordered breathing in familial dysautonomia.
Sleep medicineAntisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice.
Nucleic acids researchFemale-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome.
GastroenterologyIdentification of neuronal autophagy regulators: Combined use of iKAP and THANATOS.
Movement disorders : official journal of the Movement Disorder SocietyImprovement of chronic corneal opacity in ocular surface disease with prosthetic replacement of the ocular surface ecosystem (PROSE) treatment.
American journal of ophthalmology case reportsElongator complex is required for long-term olfactory memory formation in Drosophila.
Learning & memory (Cold Spring Harbor, N.Y.)Elongator and codon bias regulate protein levels in mammalian peripheral neurons.
Nature communicationsAmbulatory blood pressure profiles in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyStructural insights into the function of Elongator.
Cellular and molecular life sciences : CMLSIKBKAP/ELP1 gene mutations: mechanisms of familial dysautonomia and gene-targeting therapies.
The application of clinical geneticsFounder mutation in IKBKAP gene causes vestibular impairment in familial dysautonomia.
Clinical neurophysiology : official journal of the International Federation of Clinical NeurophysiologyA Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia.
LungNeurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyBasic research and model systems in familial dysautonomia: What do we know and what's next?
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyIntranasal dexmedetomidine for adrenergic crisis in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyAnimal and cellular models of familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyRBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the IKBKAP gene of familial dysautonomia.
RNA (New York, N.Y.)Phosphatidylserine improves axonal transport by inhibition of HDAC and has potential in treatment of neurodegenerative diseases.
Neural regeneration research[ORO-DENTO-FACIAL MANIFESTATIONS IN PATIENTS WITH FAMILIAL DYSAUTONOMIA].
HarefuahSudden Unexpected Death During Sleep in Familial Dysautonomia: A Case-Control Study.
SleepBGP-15 prevents the death of neurons in a mouse model of familial dysautonomia.
Proceedings of the National Academy of Sciences of the United States of AmericaProteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.
Neurobiology of diseaseFamilial dysautonomia: a disease with hidden tears.
Journal of neurologyPathological Confirmation of Optic Neuropathy in Familial Dysautonomia.
Journal of neuropathology and experimental neurologyModulation of aberrant splicing in human RNA diseases by chemical compounds.
Human geneticsThe familial dysautonomia disease gene IKBKAP is required in the developing and adult mouse central nervous system.
Disease models & mechanismsGenetic Polymorphisms in the ESR1 and VDR Genes Do Not Correlate With Osteoporosis in Patients With Familial Dysautonomia.
Journal of clinical densitometry : the official journal of the International Society for Clinical DensitometryCaring for adolescents with familial dysautonomia.
NursingPhosphatidylserine Ameliorates Neurodegenerative Symptoms and Enhances Axonal Transport in a Mouse Model of Familial Dysautonomia.
PLoS geneticsUnusual Structural Autonomic Disorders Presenting in Pediatrics: Disorders Associated with Hypoventilation and Autonomic Neuropathies.
Pediatric clinics of North AmericaSleep Apnea in Familial Dysautonomia: A Reflection of Apnea Pathogenesis.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep MedicineThe Many Faces of Elongator in Neurodevelopment and Disease.
Frontiers in molecular neuroscienceCapturing the biology of disease severity in a PSC-based model of familial dysautonomia.
Nature medicineDexmedetomidine for refractory adrenergic crisis in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyLoss of Ikbkap Causes Slow, Progressive Retinal Degeneration in a Mouse Model of Familial Dysautonomia.
eNeuroPoster 72 Teetering on the Edge: Rehabilitation in a Medically Complex Patient with Familial Dysautonomia (Hereditary Sensory Autonomic Neuropathy Type III): A Case Report.
PM & R : the journal of injury, function, and rehabilitationObstructive Sleep-Disordered Breathing Is More Common than Central in Mild Familial Dysautonomia.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep MedicineOpinion commune de la SOGC et du CCGM sur le dépistage génétique en contexte de procréation : Mise à jour à l'intention de l'ensemble des prestataires canadiens de soins de santé maternelle et de services en procréation, à l'ère des tests offerts directement aux consommateurs.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGCJoint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGCCerebral autoregulation and symptoms of orthostatic hypotension in familial dysautonomia.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and MetabolismFamilial Dysautonomia: Mechanisms and Models.
Genetics and molecular biologyIntestinal ischemia in neonates and children.
Clujul medical (1957)MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia.
Disease models & mechanisms[The function of autonomic nervous system during paroxysmal events in children and adolescents, and available diagnostic methods].
Przeglad lekarskiFamilial dysautonomia: History, genotype, phenotype and translational research.
Progress in neurobiologyTocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study.
Journal of molecular neuroscience : MNSensory and autonomic deficits in a new humanized mouse model of familial dysautonomia.
Human molecular geneticsPhosphatidylserine enhances IKBKAP transcription by activating the MAPK/ERK signaling pathway.
Human molecular geneticsAxon Transport and Neuropathy: Relevant Perspectives on the Etiopathogenesis of Familial Dysautonomia.
The American journal of pathologyIncreasing cutaneous afferent feedback improves proprioceptive accuracy at the knee in patients with sensory ataxia.
Journal of neurophysiologyMother-induced hypertension in familial dysautonomia.
Clinical autonomic research : official journal of the Clinical Autonomic Research SocietyTECPR2 mutations cause a new subtype of familial dysautonomia like hereditary sensory autonomic neuropathy with intellectual disability.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology SocietyBrainstem reflexes in familial dysautonomia. Reply to "Evidence of brainstem dysfunction in patients with familial dysautonomia and carriers of the IKBKAP mutation".
Clinical neurophysiology : official journal of the International Federation of Clinical NeurophysiologyEvidence of brainstem dysfunction in patients with familial dysautonomia and carriers of the IKBKAP mutation.
Clinical neurophysiology : official journal of the International Federation of Clinical NeurophysiologyFamilial Dysautonomia (FD) Human Embryonic Stem Cell Derived PNS Neurons Reveal that Synaptic Vesicular and Neuronal Transport Genes Are Directly or Indirectly Affected by IKBKAP Downregulation.
PloS oneChewing-induced hypertension in afferent baroreflex failure: a sympathetic response?
Experimental physiologyDimerization of elongator protein 1 is essential for Elongator complex assembly.
Proceedings of the National Academy of Sciences of the United States of AmericaIncreased frequency of rhabdomyolysis in familial dysautonomia.
Muscle & nerveContemporary perioperative management of adult familial dysautonomia (Riley-Day syndrome).
A & A case reportsRectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia.
Proceedings of the National Academy of Sciences of the United States of AmericaAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Disautonomia familiar.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Disautonomia familiar
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.
- Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.Clinical autonomic research : official journal of the Clinical Autonomic Research Society· 2026· PMID 41762390mais citado
- ELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.
- Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).Clinical autonomic research : official journal of the Clinical Autonomic Research Society· 2026· PMID 41134458mais citado
- Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.
- Prime editing of the common Familial Dysautonomia-causing c.2204 + 6T > C splicing mutation.
- Peripheral neuron phenotypes of familial dysautonomia are rescued by AAV-mediated gene therapy.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:1764(Orphanet)
- OMIM OMIM:223900(OMIM)
- MONDO:0009131(MONDO)
- GARD:7581(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
- Q2325854(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
